Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Since 2012, several novel branded drugs have entered the market with varying degrees of commercial success. Approved agents include Novo Nordisk’s Wegovy (semaglutide) and Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), and Nalpropion Pharmaceuticals’ Contrave (naltrexone / bupropion). In this report, endocrinologists compare current antiobesity drugs and discuss the attributes that the next generation of drugs should have to serve this medically important population and to succeed commercially in a potentially lucrative market.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in March 2023
Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals, Orexigen Therapeutics
Key drugs: Wegovy, Saxenda, Qsymia, Contrave/Mysimba, Xenical, phentermine